Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
In the present study, we demonstrated that cancer-associated stroma would become a new target for the treatment of pancreatic cancer. We focused on pancreatic stellate cells(PSCs) as a therapeutic target and developed a novel screening assay system to detect the activation of PSCs. Then we performed high-throughput screening using this assay, and we showed 152 compounds led PSCs into quiescent state. These data suggest that the drugs targeting PSCs may become a novel strategy for pancreatic cancer therapy.
|